TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tenaya Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.38−0.00 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $82.16M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 61.4% | -83.8% | |
| Return on assets | – | – | -67.9% | |
| Current ratio | – | 25.78 | 6.84 | |
| Diluted shares | – | 1M | 153M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Tenaya Therapeutics generated $426.07M from operations and spent $48.65M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$426.07M
Used
$48.65M
Capital expenditure$48.63M100%Dividends$00%Share buybacks$13.00K0%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$90.60M
- Cash generatingOperating cash flow above zero-$68.26M
- Return on assets improvedROA up on the prior year-65.2% → -75.5%
- Earnings backed by cashOperating cash flow above net income-$68.26M vs -$90.60M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.22 → 6.84
- No dilutionShare count did not rise85M → 153M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –